Treatment of pediatric hodgkin disease tailored to stage, mediastinal mass, and age an italian (aieop) multicenter study on 215 patients
- 15 September 1993
- Vol. 72 (6), 2049-2057
- https://doi.org/10.1002/1097-0142(19930915)72:6<2049::aid-cncr2820720642>3.0.co;2-v
Abstract
Attempting to optimize treatment results in pediatric Hodgkin disease while minimizing major side effects, at least in early-stage patients, in 1983 the Italian Association of Pediatric Hematology and Oncology (AIEOP) conceived a multicenter study tailored according to stage, bulky mediastinal mass, and age.Between December, 1983 and January, 1989, 215 evaluable patients (median age, 9.9 years, range, 1-15 years) received the AIEOP-MH 1983 Hodgkin disease protocol of low-dose radiation therapy (20-25 Gy), with three cycles of adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) for children with early-stage and favorable disease, and with alternating cycles of an eight non-cross-resistant drug combination regimen (nitrogen mustard, vincristine, procarbazine, and prednisone [MOPP]/ABVD) for 6 months for those with bulky and unfavorable disease. Patients in advanced stages received four additional courses of MOPP/ABVD as maintenance therapy.The overall survival and freedom from progression (FFP) probabilities at 7 years are 85.7% and 81.5% respectively. FFP probabilities at 7 years in Groups 1 (58 patients in Stages I and IIA with mass/thorax [M/T] < 0.33), 2 (56 patients in Stages IEA, IB, IIA with M/T > 0.33, IIB, and IIIA), and 3 (38 patients in Stages IIIB and IVA and B) were 94.8%, 81.4%, and 60.3%, respectively. Multivariate analysis showed B symptoms, M/T > 0.33, and stage to be significant, independent prognostic factors affecting survival and FFP curves.The encouraging results in early-stage disease indicate the validity of using less toxic treatment in this subgroup to maximize quality of life. Patients with bulky mediastinal disease tended to fare worse than those with M/T < 0.33 or without mediastinal involvement (FFP at 7 years: 69.4% versus 93.3%) and showed early local recurrence. In advanced stages, the eight-drug combination regimen (MOPP/ABVD) plus low-dose radiation therapy provided no major improvement in outcome; here, alternative chemotherapeutic regimens should be tested in a large, randomized, clinical trial to evaluate their efficacy and determine the frequency of delayed toxicity.Keywords
This publication has 33 references indexed in Scilit:
- Results of a changing treatment philosophy for children with stage I Hodgkin's disease: A 35-year experienceMedical and Pediatric Oncology, 1991
- Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children's Cancer Study Group.Journal of Clinical Oncology, 1990
- Stage I-II pediatric Hodgkin's disease: long-term follow-up demonstrates equivalent survival rates following different management schemes.Journal of Clinical Oncology, 1990
- Hodgkin's disease in children: Treatment with MOPP and low‐dose, extended field irradiation without laparotomy late results and toxicityMedical and Pediatric Oncology, 1990
- Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease.Journal of Clinical Oncology, 1987
- Involved field (IF) irradiation with or without chemotherapy in the management of children with Hodgkin's diseaseMedical and Pediatric Oncology, 1984
- Management of Hodgkin-s disease in children and adolescentsCancer, 1983
- An evaluation of long-term survival and treatment complications in children with Hodgkin's diseaseCancer, 1983
- Results of Treatment of 18 Children With Hodgkin Disease With MOPP Chemotherapy as the Only Treatment ModalityMedical and Pediatric Oncology, 1983
- Pediatric Hodgkin's disease. II. Results of therapyCancer, 1976